Cargando…
Inhalable exosomes outperform liposomes as mRNA and protein drug carriers to the lung()
Respiratory diseases are among the leading causes of morbidity and mortality worldwide, coupled with the ongoing coronavirus disease 2019 (COVID-19) pandemic. mRNA lipid nanoparticle (LNP) vaccines have been developed, but their intramuscular delivery limits pulmonary bioavailability. Inhalation of...
Autores principales: | Popowski, Kristen D., López de Juan Abad, Blanca, George, Arianna, Silkstone, Dylan, Belcher, Elizabeth, Chung, Jaewook, Ghodsi, Asma, Lutz, Halle, Davenport, Jada, Flanagan, Mallory, Piedrahita, Jorge, Dinh, Phuong-Uyen C., Cheng, Ke |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier, inc
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9213043/ https://www.ncbi.nlm.nih.gov/pubmed/36523538 http://dx.doi.org/10.1016/j.vesic.2022.100002 |
Ejemplares similares
-
Inhalable dry powder mRNA vaccines based on extracellular vesicles
por: Popowski, Kristen D., et al.
Publicado: (2022) -
Exosome therapeutics for lung regenerative medicine
por: Popowski, Kristen, et al.
Publicado: (2020) -
Exosome therapeutics for COVID‐19 and respiratory viruses
por: Popowski, Kristen D., et al.
Publicado: (2021) -
Advanced Nanobiomedical Approaches to Combat Coronavirus Disease of 2019
por: Lutz, Halle, et al.
Publicado: (2021) -
Bispecific Antibody Inhalation Therapy for Redirecting Stem Cells from the Lungs to Repair Heart Injury
por: Liu, Mengrui, et al.
Publicado: (2020)